About Tivic Health Systems, Inc. - Common stock (TIVC)
Tivic Health Systems, Inc. is a medical technology company focused on developing innovative solutions for chronic conditions affecting the upper respiratory tract. The company specializes in advanced neuromodulation therapies, which leverage electrical stimulation to address symptoms associated with conditions such as rhinitis and sinusitis. By utilizing its proprietary technology, Tivic Health aims to enhance patient quality of life through non-invasive treatment options that offer an alternative to traditional medication. Their commitment to research and development positions them at the forefront of transforming how patients manage their health. Read More
A wave of groundbreaking announcements this week has put the spotlight on several micro- and small-cap innovators shaping the future of healthcare, biotech, and clean energy—earning high-level regulatory, federal, and commercial support.
Shares of Tivic Health Systems, Inc. (NASDAQ: TIVC) are soaring Tuesday after the company announced it held senior-level briefings with White House officials and the U.S. Food and Drug Administration (FDA), which resulted in strong interest in potential military and defense product candidates.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
During the meeting with the White House, the company highlighted the need for advanced treatments for acute radiation syndrome in the United States and its allied countries.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it provided briefings to senior leadership at the White House and FDA which garnered significant positive interest in potential military and defense applications for its biologic and bioelectronic product candidates. Both meetings were held in Washington, D.C. on April 17th.
Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health’s common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “TIVC.”
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
In a market increasingly driven by breakthrough science and resource scarcity, a handful of sub-$2 stocks are making headlines with bold strategies, compelling partnerships, and game-changing data. From immunotherapy innovations to neuromodulation tech, metallic-rich exploration zones and wireless signal innovation, these companies are pushing the envelope—and attracting serious investor attention in the process.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company’s operations.
